204 related articles for article (PubMed ID: 7766610)
1. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
Sackett DL
Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
[TBL] [Abstract][Full Text] [Related]
2. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
Mooberry SL; Taoka CR; Busquets L
Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
[TBL] [Abstract][Full Text] [Related]
3. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
Bai RL; Pettit GR; Hamel E
J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
[TBL] [Abstract][Full Text] [Related]
4. Antimicrotubular drugs binding to vinca domain of tubulin.
Gupta S; Bhattacharyya B
Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
[TBL] [Abstract][Full Text] [Related]
5. Aging of tubulin at neutral pH: the destabilizing effect of vinca alkaloids.
Prakash V; Timasheff SN
Arch Biochem Biophys; 1992 May; 295(1):137-45. PubMed ID: 1575510
[TBL] [Abstract][Full Text] [Related]
6. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
Bai R; Pettit GR; Hamel E
Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
[TBL] [Abstract][Full Text] [Related]
7. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
Hamel E
Pharmacol Ther; 1992; 55(1):31-51. PubMed ID: 1287674
[TBL] [Abstract][Full Text] [Related]
8. The interaction of the B-ring of colchicine with alpha-tubulin: a novel footprinting approach.
Chaudhuri AR; Seetharamalu P; Schwarz PM; Hausheer FH; Ludueña RF
J Mol Biol; 2000 Nov; 303(5):679-92. PubMed ID: 11061968
[TBL] [Abstract][Full Text] [Related]
9. Effects of antimitotic agents on tubulin-nucleotide interactions.
Correia JJ
Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
[TBL] [Abstract][Full Text] [Related]
11. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
Jordan A; Hadfield JA; Lawrence NJ; McGown AT
Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of colchicine action: induced local unfolding of beta-tubulin.
Sackett DL; Varma JK
Biochemistry; 1993 Dec; 32(49):13560-5. PubMed ID: 8257691
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class.
Owellen RJ; Hartke CA; Dickerson RM; Hains FO
Cancer Res; 1976 Apr; 36(4):1499-502. PubMed ID: 1260766
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic selectivity of vinca alkaloids: a role for guanosine 5'-triphosphate?
Houghton PJ; Houghton JA; Bowman LC; Hazelton BJ
Anticancer Drug Des; 1987 Oct; 2(2):165-79. PubMed ID: 3329524
[TBL] [Abstract][Full Text] [Related]
15. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10.
Edler MC; Fernandez AM; Lassota P; Ireland CM; Barrows LR
Biochem Pharmacol; 2002 Feb; 63(4):707-15. PubMed ID: 11992639
[TBL] [Abstract][Full Text] [Related]
17. The binding of vinca domain agents to tubulin: structural and biochemical studies.
Cormier A; Knossow M; Wang C; Gigant B
Methods Cell Biol; 2010; 95():373-90. PubMed ID: 20466145
[TBL] [Abstract][Full Text] [Related]
18. Instability of pleomorphic tubulin paracrystals artificially induced by Vinca alkaloids in tissue-cultured cells.
Takanari H; Yosida T; Morita J; Izutsu K; Ito T
Biol Cell; 1990; 70(1-2):83-90. PubMed ID: 2085693
[TBL] [Abstract][Full Text] [Related]
19. Rhizoxin binding to tubulin at the maytansine-binding site.
Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
[TBL] [Abstract][Full Text] [Related]
20. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
